Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05891171 · ClinicalTrials.gov registry record · Phase 1

Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers

A Phase 1 study of Ovarian Cancer and Bladder Cancer, sponsored by Arcus Biosciences.

Active
Registry status
Phase 1
Development phase
40
Enrollment target
15
Study locations

NCT05891171: Active Phase 1 study of Ovarian Cancer and Bladder Cancer, sponsored by Arcus Biosciences.

NCT05891171 is a Phase 1 study of Ovarian Cancer and Bladder Cancer that is active but no longer recruiting, run by Arcus Biosciences. The registered enrollment target is 40 participants, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (95% lower). The trial reports 15 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05891171, a Phase 1 study of Ovarian Cancer and Bladder Cancer, is active but no longer recruiting, sponsored by Arcus Biosciences.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
40 participants
Enrollment target
15
Study locations

Study Summary

The primary purpose of this study is to assess the safety and tolerability of AB598 in participants with advanced malignancies.

Interventions

  • DRUG Fluorouracil
  • DRUG Leucovorin
  • DRUG Oxaliplatin
  • DRUG Zimberelimab
  • DRUG AB598

Study Locations (15)

Other

  • Adelaide Cancer Research - Adelaide
  • Queen Elizabeth Hospital - Adelaide
  • National Cheng Kung University Hospital - Tainan
  • Taipei Veterans General Hospital - Taipei

Florida

  • Mayo Clinic Florida - Jacksonville
  • Lake City Cancer Care, LLC. - Lake City

Ohio

  • Gabrail Cancer Center (GCC) Canton Facility - Canton
  • University Hospitals Cleveland Medical Center - Cleveland

Arizona

  • Mayo Clinic Arizona - Phoenix

Illinois

  • Affinity Health Hope and Healing Cancer Services, LLC - Hinsdale

Michigan

  • Karmanos Cancer Institute - Detroit

Minnesota

  • Mayo Clinic Rochester - Rochester

New Jersey

  • Rutgers Cancer Institute of New Jersey - New Brunswick

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2023-10-13
Est. Completion 2026-03
Phase Phase 1
Arcus Biosciences

25 total trials

What the registry record for NCT05891171 still lists

NCT05891171 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (95% lower).

The record links to 10 conditions, with Ovarian Cancer appearing as the primary indexed condition, and to 5 interventions - of which Fluorouracil is the first listed.

NCT05891171 lists 15 locations in 10 states (Other, Florida, Ohio).

Frequently Asked Questions

What is clinical trial NCT05891171 about?

NCT05891171 is a clinical study titled "Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers". The primary purpose of this study is to assess the safety and tolerability of AB598 in participants with advanced malignancies.

What is the current status of trial NCT05891171?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2023-10-13. Estimated completion is 2026-03.

What conditions does trial NCT05891171 study?

This clinical trial studies the following conditions: Ovarian Cancer, Bladder Cancer, Gastric Cancer, Cervical Cancer, Esophageal Cancer.

What interventions are being tested in trial NCT05891171?

The interventions under investigation include: Fluorouracil (DRUG), Leucovorin (DRUG), Oxaliplatin (DRUG), Zimberelimab (DRUG), AB598 (DRUG).

Who is sponsoring clinical trial NCT05891171?

This trial is sponsored by Arcus Biosciences, which has 25 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05891171 being conducted?

This trial has 15 study locations across Arizona, Florida, Illinois, Michigan, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Ovarian Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05891171's enrollment target sits among peer trials

40 227th of 322 higher than 92 of 322 other Ovarian Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Ovarian Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01306019 · 40 participants · Phase 1

    Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)

  • NCT01608152 · 40 participants

    Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors

  • NCT01668082 · 40 participants · NA

    An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection

  • NCT02015013 · 40 participants · Phase 2

    Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05891171, the US trial registry maintained by the National Library of Medicine. NCT05891171 (small enrollment · multi site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.